--CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 enhances cytokine response without additive toxicity at dose levels tested to date-- --Tumor specific expansion cohorts planned-- HAMPTON, N.J.

HAMPTON, N.J. , April 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AACR) Annual Meeting

HAMPTON, N.J. , March 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2018 . The Company will host a conference call at 4:30 p.m.

HAMPTON, N.J. , March 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2018 financial results on Thursday, March 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m.

HAMPTON, N.J. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing with the Secretary

Antibody technology provides an exciting new approach to enhance innate immune function in cancer HAMPTON, N.J. , Nov. 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the Society for

--Well tolerated; dose dependent biological effects consistent with CD40-mediated immune cell activity-- --Program development expanded based on results observed to date-- HAMPTON, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data today from

HAMPTON, N.J. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018 . “We made considerable progress in the third quarter, particularly in the development program for CDX-1140, our

HAMPTON, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018 . The Company will host a conference call at 4:30 p.m. ET today to provide an in-depth update on its pipeline and

HAMPTON, N.J. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m.